D.A. Davidson & Co’s BioCryst Pharmaceuticals BCRX Stock Holding History

D.A. Davidson & Co’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,000	Closed	-$11K	–	1157
2017 Q2	$11K	Sell	2,000 -3,000	-60%	-$18.3K	﹤0.01%	2003
2017 Q1	$42K	Sell	5,000 -500	-9%	-$3.48K	﹤0.01%	1580
2016 Q4	$34K	Hold	5,500	–	–	﹤0.01%	1744
2016 Q3	$24K	Hold	5,500	–	–	﹤0.01%	1793
2016 Q2	$15K	Buy	+5,500	New	+$17.1K	﹤0.01%	1832

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.A. Davidson & Co's BCRX Position: Q3 2017 in Review

D.A. Davidson & Co sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2017, closing a stake of 2,000 shares — an estimated $11K sold.

D.A. Davidson & Co first reported a position in BCRX in Q2 2016 and held it in 5 quarters. The position peaked at $42K in Q1 2017. 120 funds tracked by Wall St. Rank hold BCRX as of Q3 2017.

D.A. Davidson & Co reported no remaining BioCryst Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
D.A. Davidson & Co sold 2,000 BioCryst Pharmaceuticals shares in Q3 2017, an estimated $11K.
D.A. Davidson & Co first reported a position in BioCryst Pharmaceuticals in Q2 2016 and held it in 5 quarters.
D.A. Davidson & Co's BioCryst Pharmaceuticals position peaked at $42K in Q1 2017.
120 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.